Noorda Eva M, Vrouenraets Bart C, Nieweg Omgo E, Kroon Bin B R
Department of Surgery, Slotervaart Hospital, Louwesweg 6, Amsterdam 100 BK, the Netherlands.
Surg Oncol Clin N Am. 2006 Apr;15(2):373-84. doi: 10.1016/j.soc.2005.12.004.
Adjuvant perfusion to excision of a primary melanoma cannot be recommended because of its limited effect. In patients who have frequently recur-ring resectable locoregional melanoma, perfusion may provide valuable loco-regional disease control by decreasing the number of recurrences and lesions per recurrence. Randomized studies are needed to further establish the role of perfusion as an adjuvant treatment for resectable recurrences of melanoma. Unresectable limb melanoma is the primary indication for perfusion. Better response rates tend to be seen when TNF-a is used in patients who have a high tumor load. Repeat perfusion is feasible, resulting in response rates similar to those of a first perfusion for locoregional melanoma. Older age itself is not a contraindication for perfusion. The long-term health-related quality of life of survivors of melanoma who underwent treatment with perfusion is comparable to that of their healthy peers in the general Dutch population.
由于其效果有限,不建议对原发性黑色素瘤进行辅助灌注切除。在可切除的局部复发性黑色素瘤患者中,灌注可通过减少复发次数和每次复发的病灶数量来提供有价值的局部疾病控制。需要进行随机研究以进一步确定灌注作为黑色素瘤可切除复发的辅助治疗的作用。不可切除的肢体黑色素瘤是灌注的主要适应证。在肿瘤负荷高的患者中使用TNF-α时,往往会观察到更好的反应率。重复灌注是可行的,其反应率与局部黑色素瘤首次灌注相似。年龄较大本身并非灌注的禁忌证。接受灌注治疗的黑色素瘤幸存者的长期健康相关生活质量与荷兰普通人群中的健康同龄人相当。